Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Compumedics Limited ( (AU:CMP) ) has provided an update.
Compumedics Limited reports record sales orders of $32.8 million for the first half of FY25, driven by significant growth in the USA market, particularly in its sleep and Neuroscan businesses, where sales orders increased by 208%. The company is strategically positioned to capitalize on the sleep apnea diagnostic market in the USA, with initial success from its Somfit device, and is expanding its operations through new sales resources and partnerships with major independent diagnostic testing facilities. While reported revenues are slightly lower than the previous year due to timing differences in MEG sales, Compumedics maintains a positive outlook for the second half of FY25, expecting sales to exceed $55 million and EBITDA to be weighted towards this period due to initial marketing and development expenditures.
More about Compumedics Limited
Compumedics Limited is a medical device company that develops, manufactures, and commercializes diagnostic technology for sleep, brain, and ultrasonic blood flow monitoring applications. Founded in 1987 by Dr. David Burton, Compumedics has a broad international reach through its subsidiaries, Neuroscan in the US and DWL Elektronishe GmbH in Germany, serving markets in the Americas, Australia and Asia Pacific, Europe, and the Middle East. The company is recognized for its innovation, having received numerous awards, and it has been listed on the Australian Securities Exchange since 2000.
YTD Price Performance: -1.89%
Average Trading Volume: 59,016
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$48.7M
For an in-depth examination of CMP stock, go to TipRanks’ Stock Analysis page.
